Compare TBI & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBI | ELTX |
|---|---|---|
| Founded | 1985 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.5M | 185.4M |
| IPO Year | 1995 | 2014 |
| Metric | TBI | ELTX |
|---|---|---|
| Price | $6.63 | $13.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 300.4K | 136.0K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.39 | 39.29 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | $6.25 | N/A |
| Revenue Next Year | $3.90 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.18 | $7.37 |
| 52 Week High | $7.78 | $14.97 |
| Indicator | TBI | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 67.05 | 61.18 |
| Support Level | $5.44 | $9.76 |
| Resistance Level | $6.61 | $14.41 |
| Average True Range (ATR) | 0.40 | 1.07 |
| MACD | 0.05 | 0.37 |
| Stochastic Oscillator | 71.96 | 67.89 |
TrueBlue Inc is a provider of specialized workforce solutions that connect employers with talent. Its reportable segments include PeopleReady, which provides blue-collar contingent staffing and delivers on-demand and skilled labor across industries such as construction, transportation, retail, hospitality, and energy. The PeopleManagement segment offers contingent labor and outsourced industrial workforce solutions, mainly on-site at client facilities, through its OnSite and Centerline operations, focusing on workforce management and commercial driver services. PeopleSolutions delivers services focused on professional and specialized talent acquisition, as well as workforce management and compliance. The company generates the majority of its revenue from the PeopleReady segment.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.